Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Concordance in Response Assessment Incorporating Meta-Iodobenzylguanidine (123I-MIBG) and Meta-[18F]Fluorobenzylguanidine (18F-MFBG, IND#146379, NSC#853868) Imaging in Neuroblastoma

NCT06858501 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT06858501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06858501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Concordance in Response Assessment Incorporating Meta-Iodobenzylguanidine (123I-MIBG) and Meta-[18F]Fluorobenzylguanidine (18F-MFBG, IND#146379, NSC#853868) Imaging in Neuroblastoma
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Withdrawn
Start date
September 22, 2026
Completion date
December 20, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ganglioneuroblastoma, ganglioneuroblastoma, nodular, high risk neuroblastoma